HealthMap

Cardiomyopathy in Duchenne Muscular Dystrophy

Overview

• Duchenne Muscular Dystrophy (DMD) is a severe, progressive genetic muscle-wasting disorder.
• Cardiac involvement, specifically cardiomyopathy, is an intrinsic and nearly universal feature as the disease progresses into advanced stages.

Key Clinical Manifestations

• Dilated Cardiomyopathy: The most common form of heart muscle disease seen in advanced DMD, characterized by the enlargement and weakening of the ventricles.
• Myocardial Fibrosis: Progressive replacement of normal heart muscle tissue with scar tissue, particularly affecting the left ventricular wall.
• Conduction Abnormalities: Arrhythmias can develop due to the degenerative changes in the heart's electrical pathways.

Pathophysiology

• Dystrophin Deficiency: DMD is caused by the absence of dystrophin, a protein critical for maintaining the structural stability of muscle cell membranes.
• While most clinical attention is initially directed at skeletal muscle weakness, the heart muscle (myocardium) also relies heavily on dystrophin.
• Over time, the continuous mechanical stress of heart contraction leads to micro-tears, cellular damage, necrosis, and eventual replacement by fibrotic tissue.

Progression and Diagnosis in Advanced Stages

• Subclinical Onset: Cardiac involvement often develops silently during childhood and adolescence, masked by the patient's limited mobility and reduced physical activity.
• Advanced Presentation: By the second decade of life (or in advanced stages of the disease), the majority of DMD patients show clinical or subclinical signs of cardiomyopathy.
• Diagnostic Tools: Regular cardiac monitoring using echocardiography and cardiac magnetic resonance (CMR) imaging is essential to detect early functional decline before overt heart failure symptoms appear.